The first survival data on using ipilimumab and nivolumab in combination showed 69% of patients, in a trial on 142, were still alive after two years.
Both drugs were developed by Bristol-Myers Squibb.
UK doctors leading the trial said the results were “very encouraging”.
More studies on the emerging field of immunotherapy will be presented later.
The immune system is a powerful defense against infection. However, there are many “brakes” built in to stop it attacking our own tissues.
Cancer – which is a corrupted version of healthy tissue – can take advantage of those brakes to evade assault.
Ipilimumab and nivolumab are designed to cut the brakes.
Both have become standard therapies in melanoma, but most researchers believe combination therapy will be essential.
The trial showed the survival rate after two years for ipilimumab alone was 53% and no patient’s tumors had completely disappeared.
The equivalent figures for combination therapy were 69% and 22%.
However, more than half of patients had severe to life-threatening side effects which stopped their treatment.
A much larger trial involving nearly 1,000 patients has already started releasing data, but has not run for long enough to produce survival figures.
The US House Ethics Committee has voted to release its report on former Republican Representative…
ABC News has agreed to pay $15 million to President-elect Donald Trump to settle a…
South Korea’s parliament has voted to impeach President Yoon Suk Yeol over his failed attempt…
Israeli war planes have carried out more than 100 air strikes in Syria on December…
President-elect Donald Trump has threatened to impose 100% tariffs on the BRICS countries if they…
Syrian troops have withdrawn from the city of Aleppo following an offensive by rebels opposed…